Subcutaneous liraglutide ameliorates methylglyoxal-induced alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β

American Journal of Translational Research

Volumn 9, Issue 2, 2017, Pages 247-260

  Qi, Li Qin ^a   Chen, Zhou ^a   Wang, Yan Ping ^a   Liu, Xiao Ying ^a   Liu, Xiao Hong ^a   Ke, Lin Fang ^a   Zheng, Zhongjie ^a   Lin, Xiao Wei ^a   Zhou, Yu ^a   Wu, Li Juan ^a   Liu, Li Bin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Glucagon like peptide 1; Glycogen synthase kinase 3 ; Methylglyoxal; Tau protein

Indexed keywords

AMYLOID; CASPASE 3; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; LIPOFUSCIN; LIRAGLUTIDE; METHYLGLYOXAL; PROTEIN KINASE B; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL BEHAVIORAL TEST; GLUCOSE METABOLISM; MALE; MORRIS WATER MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPATIAL LEARNING; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

EID: 85014401370     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. [1] Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006239.
2. Mucke L. Alzheimer’s disease. Nature 2009; 461: 895-897.
3. Goedert M. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 2015; 349: 1255555.
4. Shen C, Chen Y, Liu H, Zhang K, Zhang T, Lin A, Jing N. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem 2008; 283: 17721-17730.
5. Sierant M, Kubiak K, Kazmierczak-Baranska J, Paduszynska A, Kuwabara T, Warashina M, Nacmias B, Sorbi S, Nawrot B. RNA interference in silencing of genes of Alzheimer’s disease in cellular and rat brain models. Nucleic Acids Symp Ser (Oxf) 2008; 52: 41-42.
6. Qi JS, Qiao JT. Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons. Neuroscience 2001; 105: 845-852.
7. Spillantini MG, Michel Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998; 21: 428-433.
8. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009; 118: 53-69.
9. Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropep-tides 2015; 52: 1-18.
10. Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr 2009; 3: 88-93.
11. Matafome P, Sena C, Seica R. Methylglyoxal, obesity, and diabetes. Endocrine 2013; 43: 472-484.
12. Pratico D. Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends Pharmacol Sci 2008; 29: 609-615.
13. Sousa Silva M, Gomes RA, Ferreira AE, Ponces Freire A, Cordeiro C. The glyoxalase pathway: the first hundred years… and beyond. Biochem J 2013; 453: 1-15.
14. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxygluco-sone in the glycation of proteins by glucose. Biochem J 1999; 344: 109-116.
15. Vistoli G, De Maddis D, Cipak A, Zarkovic N, Ca-rini M, Aldini G. Advanced glycoxidation and li-poxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013; 47 Suppl 1: 3-27.
16. Beeri MS, Moshier E, Schmeidler J, Godbold J, Uribarri J, Reddy S, Sano M, Grossman HT, Cai W, Vlassara H, Silverman JM. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev 2011; 132: 583-587.
17. Srikanth V, Westcott B, Forbes J, Phan TG, Beare R, Venn A, Pearson S, Greenaway T, Parameswaran V, Munch G. Methylglyoxal, cognitive function and cerebral atrophy in older people. J Gerontol A Biol Sci Med Sci 2013; 68: 68-73.
18. Fawver JN, Schall HE, Petrofes Chapa, RD, Zhu X, Murray IV. Amyloid-beta metabolite sensing: biochemical linking of glycation modification and misfolding. J Alzheimers Dis 2012; 30: 63-73.
19. Chen YJ, Huang XB, Li ZX, Yin LL, Chen WQ, Li L. Tenuigenin protects cultured hippocampal neurons against methylglyoxal-induced neurotoxicity. Eur J Pharmacol 2010; 645: 1-8.
20. Kuhla B, Haase C, Flach K, Luth HJ, Arendt T, Munch G. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. J Biol Chem 2007; 282: 6984-6991.
21. Munch G, Kuhla B, Luth HJ, Arendt T, Robinson SR. Anti-ageing defences against alzheimer’s disease. Biochem Soc Trans 2003; 31: 1397-1399.
22. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010; 9: 267-268.
23. Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 2003; 87: 1137-1144.
24. Gault VA, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008; 587: 112-117.
25. Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, Liu YZ. (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol 2012; 674: 280-286.
26. McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharma-cology 2014; 76: 57-67.
27. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 2011; 31: 6587-6594.
28. Sharma MK, Jalewa J, Holscher C. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem 2014; 128: 459-471.
29. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bens-inger A, Bernard A, Boe AF, Boguski MS, Brock-way KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta T, Diep E, Dolbeare TA, Donelan MJ, Dong HW, Dougherty JG, Duncan BJ, Ebbert AJ, Eichele G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss TP, Frensley C, Gates SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, Howell MP, Jeung DP, Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, Kuan CL, Lake JH, Laramee AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu Y, Luong LT, Michaels J, Morgan JJ, Morgan RJ, Mortrud MT, Mosqueda NF, Ng LL, Ng R, Orta GJ, Overly CC, Pak TH, Parry SE, Pathak SD, Pearson OC, Puchalski RB, Riley ZL, Rockett HR, Rowland SA, Royall JJ, Ruiz MJ, Sarno NR, Schaffnit K, Shapovalova NV, Sivi-say T, Slaughterbeck CR, Smith SC, Smith KA, Smith BI, Sodt AJ, Stewart NN, Stumpf KR, Sunkin SM, Sutram M, Tam A, Teemer CD, Thaller C, Thompson CL, Varnam LR, Visel A, Whitlock RM, Wohnoutka PE, Wolkey CK, Wong VY, Wood M, Yaylaoglu MB, Young RC, Young-strom BL, Yuan XF, Zhang B, Zwingman TA, Jones AR. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007; 445: 168-176.
30. Lahmy V, Long R, Morin D, Villard V, Maurice T. Mitochondrial protection by the mixed musca-rinic/sigma1 ligand ANAVEX2-73, a tetrahydro-furan derivative, in Abeta25-35 peptide-inject-ed mice, a nontransgenic Alzheimer’s disease model. Front Cell Neurosci 2014; 8: 463.
31. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1: 848-858.
32. Yang L, Zhang J, Zheng K, Shen H, Chen X. Long-term ginsenoside Rg1 supplementation improves age-related cognitive decline by promoting synaptic plasticity associated protein expression in C57BL/6J mice. J Gerontol A Biol Sci Med Sci 2014; 69: 282-294.
33. Hernandez-Nicaise ML. The nervous system of ctenophores. III. Ultrastructure of synapses. J Neurocytol 1973; 2: 249-263.
34. Bader Lange ML, St Clair D, Markesbery WR, Studzinski CM, Murphy MP, Butterfield DA. Age-related loss of phospholipid asymmetry in APP (NLh)/APP (NLh) x PS-1 (P264L)/PS-1 (P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis 2010; 38: 104-115.
35. Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008; 85: 148-175.
36. Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, Gong CX. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 2013; 37: 637-648.
37. Chou JL, Shenoy DV, Thomas N, Choudhary PK, Laferla FM, Goodman SR, Breen GA. Early dys-regulation of the mitochondrial proteome in a mouse model of Alzheimer’s disease. J Pro-teomics 2011; 74: 466-479.
38. Riederer BM, Mourton-Gilles C, Frey P, Delacourte A, Probst A. Differential phosphoryla- tion of tau proteins during kitten brain development and Alzheimer’s disease. J Neurocytol 2001; 30: 145-158.
39. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Kayed R. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-de-rived tau oligomeric seeds. J Alzheimers Dis 2014; 40 Suppl 1: S97-S111.
40. Li XH, Xie JZ, Jiang X, Lv BL, Cheng XS, Du LL, Zhang JY, Wang JZ, Zhou XW. Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation. Neuromolecular Med 2012; 14: 338-348.
41. Kuhla B, Luth HJ, Haferburg D, Boeck K, Arendt T, Munch G. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease. Ann N Y Acad Sci 2005; 1043: 211-216.
42. Hambsch B, Chen BG, Brenndorfer J, Meyer M, Avrabos C, Maccarrone G, Liu RH, Eder M, Turck CW, Landgraf R. Methylglyoxal-mediated anxiolysis involves increased protein modification and elevated expression of glyoxalase 1 in the brain. J Neurochem 2010; 113: 1240-1251.
43. Kurz A, Rabbani N, Walter M, Bonin M, Thornalley P, Auburger G, Gispert S. Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci 2011; 68: 721-733.
44. Distler MG, Palmer AA. Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights. Front Genet 2012; 3: 250.
45. Jakubcakova V, Curzi ML, Flachskamm C, Hambsch B, Landgraf R, Kimura M. The glyco-lytic metabolite methylglyoxal induces changes in vigilance by generating low-amplitude non-REM sleep. J Psychopharmacol 2013; 27: 1070-1075.
46. Chen S, An FM, Yin L, Liu AR, Yin DK, Yao WB, Gao XD. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience 2014; 256: 137-146.
47. Porter WD, Flatt PR, Holscher C, Gault VA. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. Int J Obes (Lond) 2013; 37: 678-684.
48. Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer’s disease model mice. J Neurosci 2012; 32: 13701-13708.
49. Hansen HH, Fabricius K, Barkholt P, Niehoff ML, Morley JE, Jelsing J, Pyke C, Bjerre Knud- sen L, Farr SA, Vrang N. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. J Alzheimers Dis 2015; 46: 877-888.
50. Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res 2009; 205: 265-271.
51. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsi-mons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179.
52. Hamilton A, Holscher C. Receptors for the in-cretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009; 20: 1161-1166.
53. Adams MM, Shi L, Linville MC, Forbes ME, Long AB, Bennett C, Newton IG, Carter CS, Sonntag WE, Riddle DR, Brunso-Bechtold JK. Caloric restriction and age affect synaptic proteins in hippocampal CA3 and spatial learning ability. Exp Neurol 2008; 211: 141-149.
54. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 2003; 87: 1333-1344.
55. Zhou XW, Li X, Bjorkdahl C, Sjogren MJ, Alafu-zoff I, Soininen H, Grundke-Iqbal I, Iqbal K, Winblad B, Pei JJ. Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer’s brains. Neurobiol Dis 2006; 22: 657-668.
56. Yu Y, Run X, Liang Z, Li Y, Liu F, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX. Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem 2009; 108: 1480-1494.
57. Hu M, Waring JF, Gopalakrishnan M, Li J. Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells. J Neurochem 2008; 106: 1371-1377.
58. Qi LQ, Ke LF, Liu XH, Liao LM, Ke SJ, Liu XY, Wang YP, Lin XW, Zhou Y, Wu LJ, Chen Z, Liu LB. Subcutaneous administration of liraglutide ameliorates learaning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced Alzheimer disease mouse model. Eur J Pharmacol 2016; 783: 23-32.
59. Hamdane M, Sambo AV, Delobel P, Begard S, Violleau A, Delacourte A, Bertrand P, Bena-vides J, Buee L. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem 2003; 278: 34026-34034.
60. Zhao H, Chang R, Che H, Wang J, Yang L, Fang W, Xia Y, Li N, Ma Q, Wang X. Hyperphosphorylation of tau protein by calpain regulation in retina of Alzheimer’s disease transgenic mouse. Neurosci Lett 2013; 551: 12-16.
61. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr Alzheimer Res 2005; 2: 3-18.
62. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007; 6: 464-479.